Protagonist Therapeutics Inc PTGX

$140.06 +0.87 (0.63%)

Valuation

Market cap
9,063,002,000
Revenue TTM
$46,020,000
Net income TTM
$-130,150,000
PE ratio
135.14
Forward PE
32.96
Profit margin
-282.81%
Debt to equity
0.00

Trading

Volume
760,300
Avg volume
585,120
Day's range
$138.37 – $141.71
Shares out
64,708,000
Stochastic %K
44%
Beta
1.53
Analysts
Strong Sell
Price target
$173.00

Price

Company profile

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development f...

Show more

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Industry
Biotechnology
Sector
Healthcare
Phone
510 474 0170
Website
https://www.protagonist-inc.com
Address
7707 Gateway Boulevard, Suite 140, Newark, United States

Latest news

Stocktwits

Merlintrader Sep 23, 9:57 PM
Protagonist ($PTGX): MIMRYLO Approval Triggers $275M, $300M Buyback Authorized Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/protagonist-therapeutics-stock-hub/
0 replies
CH_Expat Sep 17, 12:38 PM
$PTGX No red flags obviously.
0 replies
Cap_00 Sep 16, 4:15 PM
$PTGX I haven't called a BO since RETA... a long time ago. I've made 2 predictions that hasn't panned out... I'm going to call out PTGX buyout by JNJ by year end. Third time is the charm. Good luck boys.
1 replies
Quantumup Sep 10, 12:34 PM
Goldman Sachs🏁 $ABVX and said -- We initiate coverage of Abivax with a Buy rating and 12m price targets of €132/ADR $155. $PTGX - JNJ SYRE CRVS $ABBV PALI RHHBY MRK TEVA Here's what else Goldman Sachs had to say in its initiation report: https://x.com/Quantumup1/status/2098026971988988144?s=20
0 replies
Quantumup Sep 9, 10:42 AM
Baird reiterated $SYRE Outperform-$116 and said -- Incrementally positive on SPY003 results. $PTGX - JNJ ABBV $ABVX MRK TVRD Baird added—SPY003's positive data in ulcerative colitis does not come as much of a surprise, given the IL-23 inhibitor mechanism has been clinically validated by multiple other assets, but does continue to build on the body of data supporting Spyre's extended-interval treatment options for IBD. The most meaningful data for the core thesis will come in 2027 when we see combination data across Spyre's three mechanisms of focus (a4ẞ7, TL1A, IL-23) in a larger, placebo-controlled study (SKYLINE Part B).
0 replies
Cache_Money Sep 9, 2:20 AM
$PTGX Share buyback program announced. More great news for us longs
0 replies
IN0V8 Sep 1, 4:44 PM
$PTGX Buy Citigroup raises PT to $182 from $175
0 replies
outlawinvestor1 Aug 31, 6:35 PM
$PTGX
0 replies